

KronosMD, Inc. is offering up to \$5,000,000 of Series CF Preferred Stock under Regulation Crowdfunding, only through PicMii Crowdfunding, LLC dba Highlander Crowdfunding, a FINRA-registered funding portal. Before investing, please read the Form C, including the risk factors and financial statements, available on this page. Investing in early-stage companies is risky, and you could lose your entire investment.



[Problem](#) [Solution](#) [Business](#) [Team](#) [Terms](#) [Risks](#) [FAQs](#)

[Invest in KronosMD](#)

## Everyone goes to the dentist. Almost no one enjoys it.

We are developing S-WAVE™, a smartphone-connected 3D ultrasound tray designed to turn routine dental scans into something you can do at home, in a few minutes, with a licensed dentist reviewing the results remotely. Our AI software is being designed to compare each monthly scan with the last and flag changes early, so fewer problems become emergencies.

S-WAVE is in development and is not cleared or approved by the FDA.

[Invest in KronosMD](#)

[Read the Form C](#)



### Working lab prototype

Bench-tested; not yet tested in people

### U.S. Patent 10,799,210

Ultrasound technology for 3D dental imaging

### ~350 shareholders

Many of them dentists

### Q1 2027

Target date to request an FDA Pre-Submission meeting

### THE PROBLEM

## Dental visits are universal. So is the dread.

Almost everyone knows the routine: the appointment you keep pushing back, the time off work, the drive, the waiting room, the chair. For some people it is mild discomfort. For others, fear, cost, or distance means they stop going altogether. Problems that are simple to treat early can become costly emergencies when no one is watching.



### About 1 in 3

U.S. adults did not visit a dentist in the past year  
CDC BRFSS, 2024

### About 13%

of adults in national surveys have dental anxiety, and anxious adults are less likely to have seen a dentist in the past year  
Sukumaran et al., International Dental Journal, 2021; Nicolas et al., BMC Oral Health, 2007

### 13%

of U.S. adults report cost as a barrier to dental care  
ADA Health Policy Institute, 2024

### 63.7 million

Americans live in federally designated dental shortage areas  
HRSA, Q1 FY2026

### About 1.9 million

U.S. emergency department visits each year are for tooth disorders  
CDC/NCHS Data Brief No. 531, June 2025

Statistics are from the third-party sources shown and have not been independently verified by KronosMD.


### OUR SOLUTION

## S-WAVE™: designed to see below the surface, from home.

S-WAVE is a mouth tray lined with ultrasound sensors that fire at the same time. It is designed to capture the full dental arch in a single scan, rather than sweeping a probe tooth by tooth. The tray connects to a smartphone by cable, and scans upload to secure cloud software.



- 1 Place the tray and start a scan in the app.
- 2 The scan uploads, and our AI software compares it with your previous scans.
- 3 A licensed dentist reviews anything flagged and advises on next steps.



How S-WAVE is intended to compare with today's options

|                    | Phone-photo monitoring | Mail-in impression kits          | S-WAVE (in development)             |
|--------------------|------------------------|----------------------------------|-------------------------------------|
| What it captures   | Visible surfaces       | Tooth shape at one point in time | Designed to image below the surface |
| Ionizing radiation | None                   | None                             | None                                |
| Monthly tracking   | Yes                    | No                               | Planned                             |
| 3D output          | No                     | Yes, after mailing               | Designed to produce 3D files        |

S-WAVE is a development-stage product. We have a working laboratory prototype used for bench testing, but its performance has not been demonstrated in human studies, and the features above may change during development and FDA review.

#### THE MARKET

## Remote dental care is growing, and we believe it needs better imaging.

More people now start and track dental treatment remotely, especially clear aligner treatment. Remote care today relies largely on photos or mailed impressions, which cannot show what is happening below the surface. We intend to serve people in aligner treatment first, then expand to routine at-home monitoring.

### About 56%

of people worldwide have some form of malocclusion (misaligned teeth or bite)  
Lombardo et al., systematic review, 2020

### 500 million

consumers identified by Align Technology as its long-term clear aligner market opportunity  
Align Technology Investor Day, Nov. 23, 2020

Market data comes from third parties and does not indicate that KronosMD will capture any share of these markets.

#### OUR PLANNED BUSINESS MODEL

## How we plan to generate revenue.

If S-WAVE receives FDA authorization, we plan to sell it mainly direct to consumers, and also through dental and orthodontic practices. We expect revenue to come from two sources: the device and a monthly monitoring subscription.

#### S-WAVE tray

### About \$350

One-time purchase

#### Monitoring subscription

### About \$1 per day

Scans reviewed by licensed telehealth dentists contracted by KronosMD

#### Dental practice channel

Partnerships with private dental offices and dental service organizations (DSOs). Practices offer S-WAVE to their patients for at-home monitoring between visits.

Scans reviewed by the patient's own dentist

Over time, we may also seek licensing arrangements with aligner companies and other dental platforms. We have no such agreements today.

KronosMD has not generated revenue. Planned pricing and channels are estimates and may change. S-WAVE is not available for sale.

### Company Estimate: Illustrative Revenue in the Fifth Year After Launch

Based on our planned pricing and the assumptions below, management estimates that S-WAVE could generate about **\$94 million** in revenue in its fifth full year of commercial sales. A lower-adoption scenario produces about \$44 million. These are illustrations of what our business model could produce, not forecasts or promises, and actual results may be far lower, including zero.

| Assumption                           | Base case                    | Lower case                   |
|--------------------------------------|------------------------------|------------------------------|
| Trays sold in year 5                 | 90,000                       | 45,000                       |
| Trays sold, years 1-5 combined       | 245,000                      | 122,500                      |
| Tray price                           | \$350                        | \$350                        |
| Subscription price                   | \$1 per day (\$365 per year) | \$1 per day (\$365 per year) |
| Subscribers kept each year           | 85%                          | 75%                          |
| Average active subscribers in year 5 | About 171,000                | About 78,000                 |
| Year-5 tray revenue                  | \$31.5M                      | \$15.8M                      |
| Year-5 subscription revenue          | \$62.6M                      | \$28.3M                      |
| Year-5 total revenue                 | <b>\$94.1M</b>               | <b>\$44.0M</b>               |

**Why we believe these assumptions are reasonable:** Align Technology, the largest clear aligner maker, shipped 2.6 million clear aligner cases in 2025 (Align 2025 Form 10-K). Our base case of 90,000 trays in year 5 equals about 3.4% of that one company's annual volume, and the lower case about 1.7%, even

**Why we believe these assumptions are reasonable:** Align Technology, the largest clear aligner maker, shipped 2.6 million clear aligner cases in 2025 (Align 2025 Form 10-K). Our base case of 90,000 trays in year 5 equals about 3.4% of that one company's annual volume, and the lower case about 1.7%, even though S-WAVE is also intended for routine monitoring beyond aligner patients.

**What these estimates do not include:** costs, profit, or cash flow; any licensing or partnership revenue; the dental practice channel; or international sales. Year 1 begins only after FDA authorization, which we do not yet have and may never receive. Our target is to request an FDA Pre-Submission meeting in Q1 2027; we cannot predict when, or whether, commercial sales will begin.

*These estimates are forward-looking statements prepared in good faith by management and approved by the board of directors. They are based on assumptions that may prove wrong, have not been reviewed by any independent party, and should not be relied on as a prediction of results. The same estimates and assumptions appear in our Form C.*

WHERE WE ARE TODAY

**Patent**

We own U.S. Patent 10,799,210, which covers ultrasound technology capable of producing 3D dental images. An earlier patent we own, U.S. Patent 6,589,054, has expired.

**New filings**

We plan to file new provisional patent applications after a successful raise. Provisional applications do not guarantee that any patent will be granted.

**Laboratory data and prototype**

In 2022 we acquired the S-Ray ultrasound technology together with laboratory (bench) research data. We have since built a working laboratory prototype, which we use for bench testing. S-WAVE has not been tested in people.

**Shareholders**

About 350 people already hold KronosMD shares, many of them dentists. Their prior investment is not an indication that this offering is suitable for you.

We have not yet completed clinical testing, received FDA authorization, or signed any commercial agreements.

ROADMAP

**2022**

KronosMD formed; S-Ray ultrasound IP and research data acquired.

**2024**

S-WAVE brand completed.

**2025-2026**

Device and software design work; working laboratory prototype built and bench-tested; regulatory planning.

**Q1 2027 (target)**


Request an FDA Pre-Submission meeting.

**After this raise (planned)**

File new provisional patents, refine the laboratory prototype toward a production design, conduct testing, and prepare an FDA submission for home use.

Target dates are estimates and may be delayed.

How we plan to use the proceeds if we raise the \$5,000,000 maximum



If we raise less than the maximum, we will allocate proceeds as described in the Form C. We may change these allocations based on business needs.

Looking further ahead

Beyond imaging, we are exploring whether acoustic energy from a future version of the tray could support teeth whitening and gum care. This is early-stage research only. Any such product would require clinical trials and separate FDA authorization, and we may never develop it. This offering funds the imaging and monitoring product described above.

TEAM AND ADVISORY BOARD



**Dr. Greg Rubin**  
Chief Executive Officer

More than 40 years in the dental industry. Former clinical instructor at the USC and UNLV dental schools. Inventor and manufacturer of dental products, with experience in corporate finance and business development. Dr. Rubin also has roles at affiliated companies, described in the Form C, and does not work for KronosMD full time.

Our advisers provide guidance but are not officers or employees and do not manage the company. They serve without cash or equity compensation.



**Daniel Alter, MSc, MDT, CDT**  
Chairman, Advisory Board

Professor at New York City College of Technology; executive editor of Inside Dental Technology.



**Dr. Jonathan Greenburg, DDS**  
Advisory Board

Inventor of the Zyppah oral appliance.



**Dr. Evan Chafitz, DMD**  
Advisory Board

Oral and maxillofacial surgeon.



**Dr. Paul B. Sigfusson, DDS**  
Advisory Board

Dentist focusing on implants and TMD.

Related-party relationships, if any, are disclosed in the Form C.

## OFFERING TERMS

|                                                     |                                                           |                                                                                                                      |
|-----------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| <b>SECURITY</b><br><b>Series CF Preferred Stock</b> | <b>PRICE</b><br><b>\$1.00 per share</b>                   | <b>PRE-MONEY VALUATION</b><br><b>\$48,516,998</b><br><small>Set by the company; not an independent appraisal</small> |
| <b>MINIMUM INVESTMENT</b><br><b>\$500</b>           | <b>RAISE</b><br><b>\$10,000 target, up to \$5,000,000</b> | <b>OFFERING DEADLINE</b><br><b>April 18, 2027</b>                                                                    |

Issuer: KronosMD, Inc. (a Colorado corporation). Funding portal: PicMil Crowdfunding, LLC dba Highlander Crowdfunding. Escrow agent: Enterprise Bank & Trust. Kronos Advanced Technologies, Inc. currently holds about 89% of KronosMD's voting power and will keep control after this offering.

## Bonus shares

| Time-based (when your investment is made)               | Amount-based (single investment)            |
|---------------------------------------------------------|---------------------------------------------|
| First 7 days of the offering<br><b>20% bonus shares</b> | \$2,000 or more<br><b>10% bonus shares</b>  |
| Days 8-21<br><b>10% bonus shares</b>                    | \$5,000 or more<br><b>15% bonus shares</b>  |
|                                                         | \$10,000 or more<br><b>20% bonus shares</b> |

Time-based and amount-based bonuses combine: the maximum combined bonus is 40%, an effective price of about \$0.71 per share for those investors. Bonus shares will be issued by KronosMD after the offering closes. A single investment must meet the threshold; separate investments are not combined. Fractional shares will be rounded up. Investments through a self-directed IRA cannot receive bonus shares because of IRS rules on prohibited transactions. Investors who receive bonus shares pay a lower effective price per share than those who do not.

## Your rights as an investor

|                                                                                                                                                  |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                             |                                                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Escrow</b><br>Your funds are held in escrow until we reach the \$10,000 target. If we don't reach it by the deadline, your money is returned. | <b>Cancelling</b><br>You may cancel for any reason up to 48 hours before the deadline (or an earlier closing we announce). If the offering changes materially, you must reconfirm or your investment is cancelled and refunded. | <b>Investment limits</b><br>Non-accredited investors are limited in how much they can invest across all crowdfunding offerings in 12 months, based on income and net worth. The portal will confirm your limit. | <b>Resale restrictions</b><br>You generally cannot resell your shares for one year, and there is no public market for them. | <b>Ongoing reports</b><br>We will file an annual report (Form C-AR) with the SEC and post it on our website within 120 days after each fiscal year end. |
|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

## Key risks

Investing in KronosMD is speculative. These are some of the most important risks; read the full risk factors in the Form C before investing.

**Early stage.** S-WAVE is in development. We have a laboratory prototype only, with no product for sale and no revenue.

**Funding.** We have very little cash and depend on our parent company and this offering to continue operating. We will likely need to raise more money, which could dilute your ownership.

**Intellectual property.** We rely on one active patent. Others may design around it, and new applications may not be granted.

**Regulatory.** S-WAVE has not been cleared or approved by the FDA. The FDA could require more testing than we expect, or may never authorize it. Consumer home use may face a higher bar.

**Control.** Kronos Advanced Technologies controls KronosMD. You will have little or no influence over company decisions.

**Illiquidity and valuation.** There is no market for these shares, and resale is restricted. The price was set by the company. You may never be able to sell your shares, and you could lose your entire investment.

**Unproven technology.** We have laboratory (bench) data only. S-WAVE may not perform well enough in people to be useful.

**Competition.** Larger, well-funded companies already offer remote dental monitoring.

## ASK THE FOUNDERS

### Have a question? Ask KronosMD directly.

Post your question below and the KronosMD team will respond. All questions and answers are public so every investor can see what's been asked.

[Ask the Founders](#)

**Join the inner circle of investors**  
Connect directly with founders, ask tough questions, and participate in the community discussion.

[Log in to Comment](#) →  
It takes seconds to join

No questions yet. Be the first to ask the founders!

#### INVESTOR FAQ

• How do I invest?

• What information do I need to provide?

• When is my investment final?

• Can I invest from outside the U.S.?

• What am I buying?

• Where are the financials?

• What if you don't reach the target?

• When could I see a return?

• Can I sell my shares?

• How will I get updates?

• Are there tax implications?

## Make routine dental care something people don't dread.

Invest in KronosMD through Highlander. Please read the Form C and risk factors before investing.

[Invest in S-WAVE](#)



**Forward-looking statements.** This page contains forward-looking statements about our plans, product development, regulatory timing, pricing, and market opportunity. Words such as "plan," "intend," "designed to," "expect," "estimate," and "target" identify these statements. They are based on current assumptions and are subject to risks and uncertainties, many outside our control, that could cause actual results to differ materially. We undertake no obligation to update them except as required by law.

**Regulatory status.** S-WAVE is an investigational product in development. It has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale. Descriptions of features reflect design goals, not demonstrated performance.


**Offering.** This offering is made only through PicMii Crowdfunding, LLC dba Highlander Crowdfunding, a FINRA member and SEC-registered funding portal, under Regulation Crowdfunding. The SEC does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. Investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved.

**Third-party data.** Statistics are drawn from the sources cited and have not been independently verified by KronosMD.

**RISK DISCLAIMER.** When making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Investments on Highlander AI are speculative, illiquid, and involve a high degree of risk, including the possible loss of your entire investment. Investments are not insured by the FDIC, SIPC, or any other government agency and may be long-term or non-transferable.

Unless otherwise stated, all securities-related activity is conducted by PicMii Crowdfunding (d/b/a Highlander Crowdfunding), a funding portal registered with the U.S. Securities and Exchange Commission (SEC) and a member of the Financial Industry Regulatory Authority (FINRA). Highlander Crowdfunding is not a registered broker-dealer, and all escrow services are handled by Enterprise Bank and Trust and Luminate Bank, registered escrow agents.

Transfer agent services are provided by Highlander Fortress, LLC, a separate legal entity from Highlander Crowdfunding. Highlander Fortress does not participate in securities offerings and does not provide investment, legal, or tax advice. Regulation Crowdfunding offerings (JOBS Act Title III) made through Highlander Crowdfunding are open to both accredited and non-accredited investors. These securities offerings are not reviewed, approved, or recommended by any federal or state securities commission or regulatory authority. By accessing this site you agree to our Terms of Use, Privacy Policy and Investor User Agreement. Past performance is not indicative of future results.



© 2026 KronosMD, Inc. All rights reserved.